Habermaass Verena, Biolatti Corrado, Bartoli Francesco, Gori Eleonora, Bruni Natascia, Olivero Daniela, Marchetti Veronica
Department of Veterinary Sciences, University of Pisa, Via Livornese Lato Monte, 56122 Pisa, Italy.
Department of Microbiology, Charles River Laboratories, F26D789 Ballina, Ireland.
Vet Sci. 2024 Aug 10;11(8):364. doi: 10.3390/vetsci11080364.
Alteration in the gut microbiome in human patients with chronic liver disease is a well-known pathophysiological mechanism. Therefore, it represents both a diagnostic and therapeutical target. Intestinal dysbiosis has also been identified in dogs with chronic liver disease, but clinical trials evaluating the effectiveness of synbiotic administration are lacking. Thirty-two dogs with chronic hepatobiliary disease were equally randomized into two groups: one treated with a synbiotic complex for 4-6 weeks (TG) and one untreated control group (CG). All dogs underwent clinical evaluation, complete anamnesis, bloodwork, abdominal ultrasound, fecal bile acids, and gut microbiome evaluation at T0-T1 (after 4-6 weeks). Treated dogs showed a significant reduction in ALT activity ( = 0.007) and clinical resolution of gastrointestinal signs ( = 0.026) compared to control dogs. The synbiotic treatment resulted in a lower increase in and compared to the control group but did not affect the overall richness and number of bacterial species. No significant changes in fecal bile acids profile were detected with synbiotic administration. Further studies are needed to better evaluate the effectiveness of synbiotic administration in these patients and the metabolic pathways involved in determining the clinical and biochemical improvement.
慢性肝病患者肠道微生物群的改变是一种众所周知的病理生理机制。因此，它既是一个诊断靶点，也是一个治疗靶点。在患有慢性肝病的犬类中也发现了肠道生态失调，但缺乏评估合生元给药有效性的临床试验。32只患有慢性肝胆疾病的犬被平均随机分为两组：一组用合生元复合物治疗4 - 6周（治疗组），另一组为未治疗的对照组。所有犬在T0 - T1（4 - 6周后）均接受了临床评估、完整的病史采集、血液检查、腹部超声、粪便胆汁酸和肠道微生物群评估。与对照犬相比，治疗犬的ALT活性显著降低（ = 0.007），胃肠道症状临床缓解（ = 0.026）。与对照组相比，合生元治疗导致 和 的升高较低，但不影响细菌种类的总体丰富度和数量。合生元给药未检测到粪便胆汁酸谱有显著变化。需要进一步研究以更好地评估合生元给药对这些患者的有效性以及参与确定临床和生化改善的代谢途径。
